Australian biotech market watch 01/06/09
Monday, 01 June, 2009
All Ordinaries are up across the board by 1.5% as further signs of recovery were being warmly welcomed by stock markets around the world. In line with the rise, health indices are up 1.1% after high volumes of trading compared to a fairly deflated week last week. CSL Limited (ASX:CSL) up 45c to $29.65 on the back of the US Government placing a $230 million dollar order to produce Novel A (H1N1) influenza vaccine antigen. Other risers include Probiotec (ASX:PBP), up 11c to $1.86 and Sonic Healthcare (ASX:SHL), which lifted 2.5% to $12.12. Flurotechnics bucked the trend, plummeting a dramatic 64.3% to 25c and CathRx (ASX:CXD) dropped 4c to 51c after releasing its quarterly investor update.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
